24% af de behandlingsnaive mRCC- patienter, der får sunitinibmalat sammenlignet med 1% af patienterne, der får IFN- α.
Treatment-related hypertension was reported in approximately 24% of patients receiving sunitinib malate for treatment-naïve MRCC compared to 1% of patients receiving IFN-α.